Loading
Senti Biosciences Holdings, Inc. Stock: price and insider trades · United States
US·Mcap US$9.8M
Senti Biosciences Holdings, Inc.: what insiders have been doing
This page follows insider dealings at Senti Biosciences Holdings, Inc. as filed with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 4 filings came from 2 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
No insider has bought Senti Biosciences Holdings, Inc. shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 4 filings here. Looking back to 2022, when coverage begins, insiders filed no purchases and 2 sales.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
19
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€20,568
2 ops. · all time
Who traded when
BuySaleKanya Rajangam1 sale
Timothy K. Lu1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.31
Analyst consensus
2 analysts1.50/5
US$12.00Target US$13.50(+4194%)US$15.00
Income statement
RevenueUS$22k
EBITDA-US$60.1M-273136% margin
Net income-US$61.4M-279263.6% margin
Valuation
PER (forward)-0.3x
P/Book4.2x
Beta2.22
Balance sheet & cash
Market capUS$9.8M
Total debtUS$28.9M
Free Cash Flow-US$43.6M
Debt / Equity746%
Profitability & ownership
ROE-466.5%
ROA-65.6%
% insiders48.4%
% institutions19.0%
Last declaration on 11 March 2026
Declarations19 total
10,757 shares0Common StockSEC:0001628280-26-016795:0
80,666 shares0Common StockSEC:0001628280-26-016794:0
4,191 shares0Common StockSEC:0001628280-26-005014:0
1,384 shares0Common StockSEC:0001628280-26-005018:0
9,777,000 sharesCommon StockSEC:0001079973-25-000394:0
2,222,000 sharesCommon StockSEC:0001578563-25-000173:0
3,333,000 sharesCommon StockSEC:0000950170-25-038280:0
33,000 shares@ US$2.2593.0% of flowCommon StockSEC:0001854270-25-000034:0
78,363 shares0Common StockSEC:0001854270-25-000015:0
642,358 shares0Common StockSEC:0001854270-25-000013:0
3,922 shares@ US$4.07100.0% of flowCommon StockSEC:0001854270-25-000004:0
1,297 shares@ US$4.077.0% of flowCommon StockSEC:0001854270-25-000002:0
306,000 shares0Common StockSEC:0001854270-24-000015:0
101,000 shares0Common StockSEC:0001854270-24-000013:0
101,000 shares0Common StockSEC:0001854270-24-000017:0
30,000 shares0Common StockSEC:0001854270-22-000036:0
112,519 shares0Common StockSEC:0000950103-22-010425:0
5,750,000 shares0Common StockSEC:0000950103-22-010423:0
5,750,000 shares0Common StockSEC:0000950103-22-010424:0
19 of 19 declarations
About Senti Biosciences Holdings, Inc.
Senti Biosciences, Inc. is a biotechnology company that develops gene and cell therapies. It focuses on using synthetic biology to address serious diseases.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
